-

$undefined

N/A

(N/A)

Aptevo Therapeutics NASDAQ:APVO Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.

Location: 2401 4th Ave Ste 1050, Washington, 98121-3460, US | Website: aptevotherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-2.332M

Cash

8.714M

Avg Qtr Burn

-5.946M

Short % of Float

64.17%

Insider Ownership

3.61%

Institutional Own.

8.59%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APVO436 (mipletamig) +/- Venetoclax + Azacitidine Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG.APV-527 (4-1BB x 5T4) Details Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.